Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 14/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5237103 | 0.85 | CCR5 (0.53) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5233830 | 0.77 | CCR5 (0.50) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5234422 | 0.75 | CCR5 (0.53) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5238420 | 0.73 | CCR5 (0.51) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5234414 | 0.73 | CCR5 (0.57) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5234516 | 0.71 | CCR5 (0.51) | CCR5CYP2D6KCNH2 | |
| SCHEMBL3303563 | 0.71 | CCR5 (0.59) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5238997 | 0.70 | CCR5 (0.58) | CCR5CYP2D6KCNH2 | |
| SCHEMBL5772192 | 0.70 | CCR5 (0.42) | CCR5CYP2D6KCNH2SLC6A2SLC6A4 | |
| SCHEMBL5238345 | 0.70 | CCR5 (0.53) | CCR5CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205769-A1 | Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity | CCR5, CCR2, CCR7 | CCR5 1/4885CYP2D6 1882/4885KCNH2 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.